Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 395

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Open access
Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.·2020·Nature Medicine
DOI 10.1038/s41591-019-0716-8
Open this paper in CoChat — free account

Abstract

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)1. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition2. Crizotinib is a multikinase inhibitor with potent activity against MET3. The antitumor activity and safety of crizotinib were assessed in 69 patients with advanced NSCLCs harboring MET exon 14 alterations. Objective response rate was 32% (95% confidence interval (CI), 21–45) among 65 response-evaluable patients. Objective responses were observed independent of the molecular heterogeneity that characterizes these cancers and did not vary by splice-site region and mutation type of the MET exon 14 alteration, concurrent increased MET copy number or the detection of a MET exon 14 alteration in circulating tumor DNA. The median duration of response was 9.1 months (95% CI, 6.4–12.7). The median progression-free survival was 7.3 months (95% CI, 5.4–9.1). MET exon 14 alteration defines a molecular subgroup of NSCLCs for which MET inhibition with crizotinib is active. These results address an unmet need for targeted therapy in people with lung cancers with MET exon 14 alterations and adds to an expanding list of genomically driven therapies for oncogenic subsets of NSCLC. Results from an expansion cohort of the PROFILE 1001 trial describe the anti-tumor activity of crizotinib in people with non-small-cell lung cancer harboring a MET exon 14 alteration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-019-0716-8

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 395

Metadata

Authors
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., Awad, M. M., Shapiro, G. I., Satouchi, M., Hida, T., Hayashi, H., Murphy, D. A., Wang, S. C., Li, S., Usari, T., Wilner, K. D., & Paik, P. K.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2020-01
Volume
26
Issue
1
Pages
47-51
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/s41591-019-0716-8
OpenAlex
W3000668520
Cited by
395
References
11
FWCI
33.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. https://app.cochat.ai/papers/10.1038/s41591-019-0716-8
The paper
Drilon, A., Clark, J. W., Weiss, J., Ou, S.-H. I., Camidge, D. R., Solomon, B. J., Otterson, G. A., Villaruz, L. C., Riely, G. J., Heist, R. S., Awad, M. M., Shapiro, G. I., Satouchi, M., Hida, T., Hayashi, H., Murphy, D. A., Wang, S. C., Li, S., Usari, T., . . . Paik, P. K. (2020). Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nature Medicine. https://doi.org/10.1038/s41591-019-0716-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.